Article

Long-Term Safety and Immunogenicity of an MF59-Adjuvanted Spike Glycoprotein-Clamp Vaccine for SARS-CoV-2 in Adults Aged 18–55 Years or ≥56 Years: 12-Month Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 1 Trial

2023-03-28

Abstract excerpt

Background: We previously demonstrated the safety and immunogenicity of an MF59-adjuvanted COVID-19 vaccine based on the SARS-CoV-2 spike glycoprotein stabilised in a pre-fusion conformation by a molecular clamp using HIV-1 glycoprotein 41 sequences. Here, we describe 12-month results in adults aged 18–55 years and ≥56 years.<br><br>Methods: Phase 1, double-blind, placebo-controlled trial conducted in Australia (J...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 19dedd54-ed66-5343-a4d0-b1ecd4edfea5
DOI: 10.2139/ssrn.4401687

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Long-Term Safety and Immunogenicity of an MF59-Adjuvanted Spike Glycoprotein-Clamp Vaccine for SARS-CoV-2 in Adults Aged 18–55 Years or ≥56 Years: 12-Month Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 1 TrialDOI 10.2139/ssrn.4401687Read

First Report of a Phase 1 Randomised Trial of Molecular Clamp-Stabilised Spike Protein-Based and MF59-Adjuvanted Vaccine for SARS-CoV-2Semantic proximity Read

STUDY PROTOCOL A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): A trial conducted within the VACCELERATE networkSemantic proximity Read

Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled TrialSemantic proximity Read

Safety, Tolerability, and Immunogenicity of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults: Interim results of an open-label and randomised Phase 1 clinical trialSemantic proximity Read

Immunogenicity and safety of the homogenous booster shot of a recombinant fusion protein vaccine (V-01) against COVID-19 in healthy adult participants primed with a two-dose regimenSemantic proximity Read

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccineSemantic proximity Read

Cohort Profile: The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE)Semantic proximity Read

The COVID-19 pandemic: viral variants and vaccine efficacySemantic proximity Read

Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-BSemantic proximity Read

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 VariantSemantic proximity Read

Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M TM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trialSemantic proximity Read

COVID-19 vaccinations: The unknowns, challenges, and hopes.Semantic proximity Read